IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$543.45 USD
+2.51 (0.46%)
Updated May 17, 2024 04:00 PM ET
After-Market: $543.42 -0.03 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IDXX 543.45 +2.51(0.46%)
Will IDXX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IDXX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDXX
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics
IDXX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Idexx Laboratories (IDXX) Tops Q1 Earnings Estimates
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
Other News for IDXX
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
IDEXX Laboratories to Present at Stifel Conference and Announces 2024 Investor Day
Idexx Laboratories price target lowered by $24 at Morgan Stanley, here's why